The perspective of anti-HER2 therapy for HER2 positive breast cancer

被引：0
|
作者：
Iwata, Hiroji [1 ]
机构：
[1] Aichi Canc Ctr Hosp, Dept Breast Oncol, Nagoya, Aichi, Japan
来源：
ANNALS OF ONCOLOGY | 2015年 / 26卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
ISY3-3
引用
收藏
页码：11 / 11
页数：1
相关论文
共 50 条
  • [1] Anti-HER2 Drugs for the Treatment of Advanced HER2 Positive Breast Cancer
    Stanowicka-Grada, Malwina
    Senkus, Elzbieta
    [J]. CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2023, 24 (11) : 1633 - 1650
  • [2] Anti-HER2 neoadjuvant and adjuvant therapies in HER2 positive breast cancer
    Guarneri, V.
    Barbieri, E.
    Dieci, M. V.
    Piacentini, F.
    Conte, P.
    [J]. CANCER TREATMENT REVIEWS, 2010, 36 : S62 - S66
  • [3] Anti-HER2 Drugs for the Treatment of Advanced HER2 Positive Breast Cancer
    Malwina Stanowicka-Grada
    Elżbieta Senkus
    [J]. Current Treatment Options in Oncology, 2023, 24 : 1633 - 1650
  • [4] Her2 positive subtype and breast cancer brain metastasis: any effect of anti-Her2 targeted therapy?
    Kadri Altundag
    [J]. Journal of Neuro-Oncology, 2017, 135 : 639 - 639
  • [5] HER2 testing and its predictive utility in anti-HER2 breast cancer therapy
    Advani, Pooja P.
    Crozier, Jennifer A.
    Perez, Edith A.
    [J]. BIOMARKERS IN MEDICINE, 2015, 9 (01) : 35 - 49
  • [6] Her2 positive subtype and breast cancer brain metastasis: any effect of anti-Her2 targeted therapy?
    Altundag, Kadri
    [J]. JOURNAL OF NEURO-ONCOLOGY, 2017, 135 (03) : 639 - 639
  • [7] ESAM reduces anti-HER2 therapy sensitivity by activating mTOR pathway in HER2 positive breast cancer
    Wu, Jiong
    Zhou, Xujie
    Chi, Yayun
    Xue, Jingyan
    [J]. CANCER RESEARCH, 2023, 83 (05)
  • [8] Differential response of HER2-positive breast cancer to anti-HER2 therapy based on HER2 protein expression level
    Atallah, N. M.
    Alsaleem, M.
    Toss, M. S.
    Mongan, N. P.
    Rakha, E.
    [J]. BRITISH JOURNAL OF CANCER, 2023, 129 (10) : 1692 - 1705
  • [9] Differential response of HER2-positive breast cancer to anti-HER2 therapy based on HER2 protein expression level
    N. M. Atallah
    M. Alsaleem
    M. S. Toss
    N. P. Mongan
    E. Rakha
    [J]. British Journal of Cancer, 2023, 129 : 1692 - 1705
  • [10] BREAST CANCER BIOMARKERS AND HER2 TESTING AFTER 10 YEARS OF ANTI-HER2 THERAPY
    Ross, Jeffrey S.
    [J]. DRUG NEWS & PERSPECTIVES, 2009, 22 (02) : 93 - 106
12345